Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial

• Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose (5 mcg) booster.

• The study also exhibited that booster vaccination generated strong immune responses, both with respect to response magnitude and duration of response for at least three months post-boost.

• Twelve participants in this arm received 5 mcg of ARCT-154 at least five months after receiving two primary doses of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty.

• Related: Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study.

• Results show that a single 5 mcg dose of ARCT-154 led to neutralizing antibody responses that remained 30-fold elevated over baseline (pre-boost) levels at three months after vaccination.

• 28-fold and 40-fold increases in neutralizing antibody responses from baseline levels were seen on Day 15 and Day 29.

• Data for Beta strain also demonstrated notable durability of neutralizing antibody response with 24-fold at three months after booster vaccination, compared to 26-fold and 31-fold over baseline on Day 15 and Day 29, respectively.

• Price Action: ARCT shares are down 9.61% at $20.42 during the market session on the last check Thursday.

See more from Benzinga

• Novavax Seeks Approval For COVID-19 Shot Among Adolescents In Britain

• Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.